Health Canada has approved MDK-Nitisinone medication for the treatment of hereditary tyrosinemia type 1 in 2016.
IN THE EUROPEAN UNION
European Medicines Agency (EMA) has approved Nitisinone MDK medication for the treatment of hereditary tyrosinemia type 1 in 2017.
Accessible solutions for Tyrosinemia
Nitisinone (MDK) is indicated for the treatment of patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone (MDK) stops the build-up of toxic substances which cause the severe liver and kidney problems in patients with HT-1. Treatment with nitisinone was found to result in reduced risk for the development of hepatocellular carcinoma, compared to historical data on treatment with dietary restriction alone. Early initiation of treatment was associated with a further reduced risk for the development of hepatocellular carcinoma.
Affordable health solutions
MendeliKABS is dedicated to the treatment of rare diseases. We integrate high-level expertise to offer affordable health solutions for orphan diseases and provide drugs manufacturing facilities in full compliance with international regulations and standards.
MDK-Nitisinone or Nitisinone MDK are available in these following countries:
|• Austria||• Belgium||• Bulgaria|
|• Canada||• Cyprus||• Croatia|
|• Czech Republic||• Denmark||• Estonia|
|• Finland||• France||• Germany|
|• Greece||• Hungary||• Iceland|
|• Ireland||• Italy||• Latvia|
|• Lithuania||• Luxembourg||• Malta|
|• Netherlands||• Norway||• Poland|
|• Portugal||• Romania||• Slovakia|
|• Slovenia||• Spain||• Sweden|
|• United Kingdom|